T

Talis Biomedical Corp
NASDAQ:TLIS

Watchlist Manager
Talis Biomedical Corp
NASDAQ:TLIS
Watchlist
Price: 2.84 USD Market Closed
Market Cap: $90m

Operating Margin

-11 353.4%
Current
Declining
by 6 713.3%
vs 3-y average of -4 640.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-11 353.4%
=
Operating Income
$-46.3m
/
Revenue
$408k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-11 353.4%
=
Operating Income
$-46.3m
/
Revenue
$408k

Peer Comparison

Country Company Market Cap Operating
Margin
US
Talis Biomedical Corp
NASDAQ:TLIS
90m USD
Loading...
US
Abbott Laboratories
NYSE:ABT
188.9B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
188.5B USD
Loading...
US
Stryker Corp
NYSE:SYK
137.1B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
135.3B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
129.9B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
58.8B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
48.7B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
55.3B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
49B USD
Loading...
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
37.3B USD
Loading...

Market Distribution

Lower than 96% of companies in the United States of America
Percentile
4rd
Based on 14 112 companies
4rd percentile
-11 353.4%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Talis Biomedical Corp
Glance View

Market Cap
90m USD
Industry
Health Care

Talis Biomedical Corp. develops and commercialize innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Menlo Park, California. The company went IPO on 2021-02-12. (Talis) Is engaged in developing molecular diagnostic tests for infectious diseases at the point of care. The firm is focused on developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions. Talis is developing the Talis One platform, a cloud-enabled molecular diagnostic platform. The Talis One platform comprises a compact instrument, single-use test cartridges and software, including a central cloud database, which work together and are designed to provide central laboratory levels of accuracy. The platform is designed for use in non-laboratory settings, such as physicians’ offices, hospital emergency departments, urgent care clinics, ambulatory surgery centers, assisted living facilities, and cancer treatment and dialysis centers. The firm is also developing Talis One tests for respiratory infections, infections related to women’s health and sexually transmitted infections.

TLIS Intrinsic Value
Not Available
T
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-11 353.4%
=
Operating Income
$-46.3m
/
Revenue
$408k
What is Talis Biomedical Corp's current Operating Margin?

The current Operating Margin for Talis Biomedical Corp is -11 353.4%, which is below its 3-year median of -4 640.1%.

How has Operating Margin changed over time?

Over the last 3 years, Talis Biomedical Corp’s Operating Margin has decreased from -1 179.9% to -11 353.4%. During this period, it reached a low of -11 353.4% on Jul 30, 2024 and a high of -1 179.9% on May 30, 2021.

Back to Top